Eric R Craig1, Angelina I Londoño2, Lyse A Norian3, Rebecca C Arend4. 1. School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. 2. Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, USA. 3. Department of Nutrition Sciences and Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA. 4. Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: rarend@uabmc.edu.
Abstract
OBJECTIVE: Epithelial ovarian cancer continues to be the deadliest gynecologic malignancy. Patients with both diabetes mellitus and obesity have poorer outcomes, yet research correlating metabolic abnormalities, such as metabolic syndrome, to ovarian cancer risk and outcomes is lacking. This article reviews the literature regarding metabolic derangements and their relationship to epithelial ovarian cancer, with a focus on potential mechanisms behind these associations. METHODS: PubMed and Google Scholar were searched for articles in the English language regarding epithelial ovarian cancer, obesity, diabetes mellitus, and metabolic syndrome, with a focus on studies conducted since 1990. RESULTS: Obesity, type II diabetes mellitus, and metabolic syndrome have been associated with poor outcomes in epithelial ovarian cancer. More studies investigating the relationship between metabolic syndrome and epithelial ovarian cancer are needed. A variety of pathologic factors may contribute to cancer risk in patients with metabolic derangements, including altered adipokine and cytokine expression, altered immune responses to tumor cells, and changes in pro-tumorigenic signaling pathways. CONCLUSION: More research is needed to examine the effects of metabolic syndrome on epithelial ovarian cancer risk and mortality, as well as the underlying pathophysiologies in patients with obesity, diabetes mellitus, and metabolic syndrome that may be targeted for therapeutic intervention.
OBJECTIVE:Epithelial ovarian cancer continues to be the deadliest gynecologic malignancy. Patients with both diabetes mellitus and obesity have poorer outcomes, yet research correlating metabolic abnormalities, such as metabolic syndrome, to ovarian cancer risk and outcomes is lacking. This article reviews the literature regarding metabolic derangements and their relationship to epithelial ovarian cancer, with a focus on potential mechanisms behind these associations. METHODS: PubMed and Google Scholar were searched for articles in the English language regarding epithelial ovarian cancer, obesity, diabetes mellitus, and metabolic syndrome, with a focus on studies conducted since 1990. RESULTS:Obesity, type II diabetes mellitus, and metabolic syndrome have been associated with poor outcomes in epithelial ovarian cancer. More studies investigating the relationship between metabolic syndrome and epithelial ovarian cancer are needed. A variety of pathologic factors may contribute to cancer risk in patients with metabolic derangements, including altered adipokine and cytokine expression, altered immune responses to tumor cells, and changes in pro-tumorigenic signaling pathways. CONCLUSION: More research is needed to examine the effects of metabolic syndrome on epithelial ovarian cancer risk and mortality, as well as the underlying pathophysiologies in patients with obesity, diabetes mellitus, and metabolic syndrome that may be targeted for therapeutic intervention.
Authors: Yueying Liu; Matthew N Metzinger; Kyle A Lewellen; Stephanie N Cripps; Kyle D Carey; Elizabeth I Harper; Zonggao Shi; Laura Tarwater; Annie Grisoli; Eric Lee; Ania Slusarz; Jing Yang; Elizabeth A Loughran; Kaitlyn Conley; Jeff J Johnson; Yuliya Klymenko; Lana Bruney; Zhong Liang; Norman J Dovichi; Bentley Cheatham; W Matthew Leevy; M Sharon Stack Journal: Cancer Res Date: 2015-11-16 Impact factor: 12.701
Authors: Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos Journal: N Engl J Med Date: 2003-01-16 Impact factor: 91.245
Authors: Renée T Fortner; Elizabeth M Poole; Nicolas A Wentzensen; Britton Trabert; Emily White; Alan A Arslan; Alpa V Patel; V Wendy Setiawan; Kala Visvanathan; Elisabete Weiderpass; Hans-Olov Adami; Amanda Black; Leslie Bernstein; Louise A Brinton; Julie Buring; Tess V Clendenen; Agnès Fournier; Gary Fraser; Susan M Gapstur; Mia M Gaudet; Graham G Giles; Inger T Gram; Patricia Hartge; Judith Hoffman-Bolton; Annika Idahl; Rudolf Kaaks; Victoria A Kirsh; Synnove Knutsen; Woon-Puay Koh; James V Lacey; I-Min Lee; Eva Lundin; Melissa A Merritt; Roger L Milne; N Charlotte Onland-Moret; Ulrike Peters; Jenny N Poynter; Sabina Rinaldi; Kim Robien; Thomas Rohan; Maria-José Sánchez; Catherine Schairer; Leo J Schouten; Anne Tjonneland; Mary K Townsend; Ruth C Travis; Antonia Trichopoulou; Piet A van den Brandt; Paolo Vineis; Lynne Wilkens; Alicja Wolk; Hannah P Yang; Anne Zeleniuch-Jacquotte; Shelley S Tworoger Journal: Int J Cancer Date: 2019-01-14 Impact factor: 7.396